Optax (Oxybuprocaine Hydrochloride, Fluorescein Sodium)

Oxybuprocaine blocks voltage‑gated sodium channels on corneal nerve endings, preventing the initiation and propagation of nerve impulses. This reversible blockade results in rapid loss of sensation on the ocular surface, allowing clinicians to perform examinations or minor interventions without causing pain to the patient.

The dose of Optax is determined by the prescribing clinician. Typically, one to two drops are instilled into the conjunctival sac of the affected eye shortly before the procedure or diagnostic staining, but the exact volume and frequency depend on the specific clinical situation.

Safety data for Optax in pregnancy and lactation are limited. It should only be used when clearly needed, after a careful risk‑benefit assessment by the treating physician. Women who are pregnant or breastfeeding should discuss potential risks with their healthcare provider before use.

To order Optax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Optax combines oxybuprocaine, a fast‑acting anesthetic, with fluorescein for diagnostic staining. Compared with agents such as proparacaine or tetracaine, oxybuprocaine provides a similarly rapid onset but may have a slightly shorter duration. The added fluorescein component gives Optax a dual function that single‑agent anesthetics lack, making it useful when both anesthesia and surface visualization are required.

Optax should be stored at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed in its original packaging. Do not freeze the solution, and discard any product that appears discolored or contains particles.

Optax is applied topically to the eye. The patient should tilt the head back slightly, pull down the lower eyelid to create a small pocket, and instill the prescribed number of drops into the conjunctival sac. After administration, the patient should keep the eye closed for a few seconds to allow even distribution.

Serious risks, although rare, include corneal epithelial toxicity, severe allergic reactions such as anaphylaxis, persistent corneal ulceration, and a possible rise in intraocular pressure. Any signs of intense pain, vision loss, swelling, or allergic symptoms should prompt immediate medical evaluation.

Optax should not be used in individuals with known hypersensitivity to oxybuprocaine, fluorescein, or any excipients in the formulation. It is also contraindicated in eyes with active severe infection unless directed by a specialist, and in patients where the risk of corneal toxicity outweighs the clinical benefit.